Physician profile
Roy Barski
NPI 1497258164
$2,266.63
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $281 · 2021: $1,245 · 2022: $606 · 2023: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $134.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $579.10 | 2020-2023 | |
| Janssen Pharmaceuticals, INC | $298.27 | 2020-2022 | |
| Amgen INC. | $252.13 | 2020-2022 | |
| Astrazeneca Pharmaceuticals Lp | $215.79 | 2021-2022 | |
| Pfizer INC. | $177.40 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.02 | 2020-2022 | |
| Abbvie INC. | $97.93 | 2020-2022 | |
| Biogen, INC. | $97.33 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $91.07 | 2020-2021 | |
| Lilly USA, LLC | $79.82 | 2021-2022 | |
| Amarin Pharma, INC. | $77.15 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $59.50 | 2020-2021 | |
| Almatica Pharma LLC | $26.47 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $20.38 | 2020 | |
| Corium, LLC | $18.85 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $18.56 | 2022 | |
| Genentech USA, INC. | $16.98 | 2021 | |
| Abbott Laboratories | $14.90 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.68 | 2021 | |
| Glaxosmithkline, LLC. | $11.30 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Barski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.